Protagonist Therapeutics (PTGX) Operating Expenses (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Operating Expenses of $60.0 million for Q1 2026, up 3.85% sequentially from $57.8 million in Q4 2025, and up 26.0% YoY from $47.6 million in Q1 2025.
Protagonist Therapeutics (PTGX) Operating Expenses (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Operating Expenses for 12 years, with the latest figure at $60.0 million in Q1 2026.
- Quarterly Operating Expenses rose 26.0% year-over-year to $60.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $216.5 million (up 19.91% YoY) and the FY2025 annual result came in at $204.1 million, up 12.42% from the prior year.
- Operating Expenses rose to $60.0 million in Q1 2026 per PTGX's latest filing, from $57.8 million in the prior quarter.
- Over five years, Operating Expenses peaked at $60.0 million in Q1 2026 and troughed at $32.3 million in Q3 2022.
- A 5-year average of $44.6 million and a median of $43.9 million in 2024 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 55.02% in 2022, down 26.94% in 2022.
- Over 5 years, Operating Expenses stood at $36.5 million in 2022, then gained by 1.19% to $37.0 million in 2023, then gained by 18.69% to $43.9 million in 2024, then surged by 31.77% to $57.8 million in 2025, then increased by 3.85% to $60.0 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $60.0 million, $57.8 million, and $51.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 54.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.71 Mn |
| Mar 31, 2026 | 60.02 Mn |
| Dec 31, 2025 | 57.79 Mn |
| Sep 30, 2025 | 51.13 Mn |
| Jun 30, 2025 | 47.59 Mn |
| Mar 31, 2025 | 47.63 Mn |
| Dec 31, 2024 | 43.86 Mn |
| Sep 30, 2024 | 46.13 Mn |
| Jun 30, 2024 | 42.96 Mn |
| Mar 31, 2024 | 48.64 Mn |
| Dec 31, 2023 | 36.95 Mn |
| Sep 30, 2023 | 38.33 Mn |
| Jun 30, 2023 | 42.35 Mn |
| Mar 31, 2023 | 36.02 Mn |
| Dec 31, 2022 | 36.52 Mn |
| Sep 30, 2022 | 32.30 Mn |
| Jun 30, 2022 | 42.30 Mn |
| Mar 31, 2022 | 46.83 Mn |
| Dec 31, 2021 | 45.63 Mn |
| Sep 30, 2021 | 44.21 Mn |